Indian Journal of Surgical Oncology

, Volume 3, Issue 3, pp 262–266

Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer – Single Center Experience

  • Rajshekhar C. Jaka
  • S. P. Somashekhar
  • Shabber S. Zaveri
  • Zahoor Ahmed
  • K. R. Ashwin
Original Article


Majority of intraperitoneal (IP) chemotherapy complications were related to the chemoport. Aim of our study was to find the means of reducing complications of IP chemoport, to increase the benefits of IP chemotherapy. During January 2007 to December 2010, hundred consecutive patients of stage III epithelial ovarian cancer who had optimal cytoreduction underwent chemoport insertion during laparotomy. Initial 20 cases had 14.3F Bard IP chemoport, and later cases had 9.6Fr single lumen venous port inserted intraperitoneally. Entry point into the peritoneum was single, 6 cm lateral to the umbilicus and double purse-string suture taken around the catheter to prevent peri-catheter backflow of ascitic fluid or drug. Modified IP chemotherapy regimen (SWOG-9912 trial) was used. Age of the patient ranged from 34 years to 76 years. In total 600 cycles, 516 cycles (86 %) were completed. Seventy patients (70 %) received all the 6 cycles by IP route. Two in the initial 10 patients had vaginal leak, for whom first 2 cycles were given by IV route and then shifted to IP route. Subsequently all cases had double layer closure of vaginal vault. Nine patients (9 %) had port related complications, in which 8 were transient. Catheter block was seen in 5 cases, of which 4 salvaged by heparin injection lock for 2 h and in subsequent cases IV port access catheter with valve replaced the fenestrated IP catheter. None of the IV catheters had the block. Four cases had backflow of fluid around catheter collecting around the port chamber site. Two patients had severe abdominal pain due to dense adhesions and further cycles were completed by IV route. Cisplatin was replaced with carboplatin in 5 cases with severe toxicity. Longest follow-up is 4 years with median follow up of 1.8 years.70 % are disease free on follow up. Local recurrence rate was 18 and systemic in 8 cases. Mortality rate is 4 %. Complications of IP ports are low when insertion is done meticulously with a dedicated team. With modified IP dose and drug regimen, side effects are less and most patients can complete all the desired cycles.


Intraperitoneal chemotherapy Ovarian cancer Chemotherapy 


  1. 1.
    Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955PubMedCrossRefGoogle Scholar
  2. 2.
    Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007PubMedGoogle Scholar
  3. 3.
    Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43PubMedCrossRefGoogle Scholar
  4. 4.
    Walker JL, Armstrong D, Huang H et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:27–32PubMedCrossRefGoogle Scholar
  5. 5.
    Davidson SA, Rubin SC, Markman M et al (1991) Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 41:101–106PubMedCrossRefGoogle Scholar
  6. 6.
    Makhija S, Leitao M, Sabbatini P et al (2001) Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 81:77–81PubMedCrossRefGoogle Scholar
  7. 7.
    Braly P, Doroshow J, Hoff S (1986) Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Gynecol Oncol 25:319–333PubMedCrossRefGoogle Scholar
  8. 8.
    Runowicz CD, Dottino PR, Shafir MK, Mark MA, Cohen CJ (1986) Catheter complications associated with intraperitoneal chemotherapy. Gynecol Oncol 24:41–50PubMedCrossRefGoogle Scholar
  9. 9.
    Jenkins J, Sugarbaker PH, Gianola FJ, Myers CE (1982) Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet 154:858–864PubMedGoogle Scholar
  10. 10.
    Piccart MJ, Speyer JL, Markman M et al (1985) Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 12:90–96PubMedGoogle Scholar
  11. 11.
    Bilsel Y, Balik E, Bugra D, Yamaner S, Akyuz A (2005) A case of protrusion of an intraperitoneal chemotherapy catheter through rectum. Int J Gynecol Cancer 15:171–174PubMedCrossRefGoogle Scholar
  12. 12.
    Ghosh K, Geller MA, Twiggs LB (2000) Erosion of an intraperitoneal chemotherapy catheter resulting in an enterovaginal fistula. Gynecol Oncol 77:327–329PubMedCrossRefGoogle Scholar
  13. 13.
    Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA (2009) Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution’s experience. Gynecol Oncol 114(3):420–423PubMedCrossRefGoogle Scholar
  14. 14.
    Black D, Levine DA, Nicoll L et al (2008) Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 109(1):39–42PubMedCrossRefGoogle Scholar
  15. 15.
    Lesnock JL, Richard SD, Zorn KK et al (2010) Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol 116(3):345–350PubMedCrossRefGoogle Scholar
  16. 16.
    Landrum LM, Gold MA, Moore KN et al (2008) Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol 108:342PubMedCrossRefGoogle Scholar
  17. 17.
    Fujiwara K, Amstrong D, Morgan M, Markman M (2007) Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 17:1–20PubMedCrossRefGoogle Scholar
  18. 18.
    Alberts DS, Markman M, Armstong D, Rothenberg ML, Muggia F, Howell SB (2002) Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 20:3944–3946PubMedGoogle Scholar
  19. 19.
    Howell SB, Pfeifle CE, Wung WE et al (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851PubMedGoogle Scholar
  20. 20.
    Casper ES, Kelsen DP, Alcock NW et al (1983) IP cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 67:235–238PubMedGoogle Scholar
  21. 21.
    Lopez JA, Krikorian JG, Reich SD et al (1985) Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol 20:1–9PubMedCrossRefGoogle Scholar
  22. 22.
    Pretorius RG, Hacker NF, Berek JS et al (1983) Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67:1085–1092PubMedGoogle Scholar
  23. 23.
    Barlin JN, Dao F, Zgheib NB et al (2012) Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol [Epub ahead of print]Google Scholar
  24. 24.
    Konner JA, Grabon D, Pezzulli S et al (2009) A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizuab as first-line chemotherapy for optial stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol (Meeting abstracts) 27:5539. AbstractGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2012

Authors and Affiliations

  • Rajshekhar C. Jaka
    • 1
  • S. P. Somashekhar
    • 1
  • Shabber S. Zaveri
    • 1
  • Zahoor Ahmed
    • 1
  • K. R. Ashwin
    • 1
  1. 1.Department of Surgical OncologyManipal Comprehensive Cancer Center, Manipal HospitalBangaloreIndia

Personalised recommendations